Skip to content

Monovisc Injectable Intra-Articular Device

by Anika Therapeutics, Inc.

PMA P090031

Active United States

PMA

Valid until

No expiry

PMA approval is not time-limited

FDA recalls

None found

in data synced 22 Oct 2026

Documents

PMA P090031↗

FDA record

Trust

Unverified

Source FDA PMA, synced 22 Oct 2026.

Regulatory status

as of registry sync 22 Oct 2026

RegionAuthorizationNumberDateStatus
United StatesFDA PMAAPPR Approved NumberP090031 Date25 Feb 2014ApprovedStatusActive

Official records

From the FDA record

FDA PMA P090031

Received by the FDA
29 Dec 2009
FDA decision
25 Feb 2014
FDA review time
1,519 days from receipt to decision
Docket number
14M-0254
Approval order statement, verbatim
APPROVAL FOR THE MONOVISC INJECTABLE INTRA-ARTICULAR DEVICE. THIS DEVICE IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS (OA) OF THE KNEE IN PATIENTS WHO HAVE FAILED TO RESPOND ADEQUATELY TOCONSERVATIVE NON-PHARMACOLOGIC THERAPY AND TO SIMPLE ANALGESICS (E.G., ACETAMINOPHEN).

From the FDA PMA record P090031 (openFDA), as read on 22 Oct 2026. Quoted as published, gaps included; nothing on this list is generated.

Coverage

1 jurisdiction

United States of America
  • Active
  • Expiring
  • Withdrawn
  • Listed
  • Not covered

United States — FDA PMA Active

Specification

PMA

Trade name
Monovisc
Generic name
Acid, hyaluronic, intraarticular
PMA number
FDA product code
MOZ
Device class
Class III
Advisory committee
Orthopedic
FDA decision
APPR Approved

Overview

AI-generated summary, 18 Sep 2026

Written by a language model from registry data. Not verified by deviCERTS or the manufacturer. The registry data above is the record.

The Monovisc Injectable Intra-Articular Device is a hyaluronic acid-based viscosupplement classified as an intraarticular acid. It is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have not responded adequately to conservative non-pharmacologic therapy and simple analgesics.

This device is supplied as a single-use, sterile injectable solution for intra-articular administration. It is intended for use in clinical settings by healthcare professionals and has received FDA PMA approval under PMA number P090031. The device is available in a 4ml formulation containing 88mg of hyaluronic acid, with multiple registration numbers for tracking and distribution.

Devices cleared under P090031

5 devices · FDA GUDID

Devices that FDA's GUDID lists as cleared or approved under this submission number. One submission usually covers a whole product family, so the sizes and models are listed here once.

Devices cleared under P090031
UDI-DISize and differences
Monovisc
MAPLESTONE DEVELOPMENTS LIMITED
N/A05065026658029 —On the market
Monovisc
PAVAN TRADING LTD
None05060548950033 —On the market
Monovisc
ALLY MEDICAL SUPPLIES LTD
None05060459970090 —On the market
MONOVISC 277515
SAIMA GLOBAL FARMA S.L.
27751508437027710018 —On the market
Monovisc 690-016
Anika Therapeutics, Inc.
690-01610886705025183 —On the market

Similar devices

Other devices filed under FDA product code MOZ (Acid, Hyaluronic, Intraarticular).

Other devices from Anika Therapeutics, Inc.

See all devices from Anika Therapeutics, Inc. →